Complete List of Compounds for Hair Loss Treatment
1. Approved Drugs
Minoxidil
Category: Potassium channel opener
Mechanism: Vasodilation, prolongs hair follicle anagen phase
Indications: Androgenetic alopecia, alopecia areata
Route: Mainly topical
Finasteride
Category: Type 2 5α-reductase inhibitor
Mechanism: Reduces DHT production
Indications: Male androgenetic alopecia
Route: Oral
Dutasteride
Category: Type 1 + 2 5α-reductase inhibitor
Mechanism: Stronger DHT reduction
Indications: Male androgenetic alopecia (off-label)
Route: Oral / topical
Spironolactone
Category: Anti-androgen
Mechanism: Blocks androgen receptor
Indications: Female androgenetic alopecia
Route: Oral / topical
Tofacitinib
Category: JAK inhibitor
Indications: Moderate to severe alopecia areata
Route: Oral / topical
Baricitinib
Category: JAK inhibitor
Indications: Alopecia areata (FDA-approved)
Route: Oral
Ritlecitinib
Category: JAK3/TEC inhibitor
Indications: Alopecia areata, androgenetic alopecia
Route: Oral
2. Clinical-Stage & Promising Drugs
Clascoterone
Category: Topical androgen receptor antagonist
Mechanism: Blocks AR locally without lowering systemic DHT
Indications: Male & female androgenetic alopecia
Route: Topical
Setipiprant
Category: CRTh2/PGD2 antagonist
Indications: Androgenetic alopecia
Route: Oral / topical
Fevipiprant
Category: Potent CRTh2 antagonist
Indications: Androgenetic alopecia, asthma
Route: Oral
RU58841
Category: Topical androgen receptor antagonist
Indications: Androgenetic alopecia
Route: Topical (research / compounded)
WAY-316606
Category: GSK-3β inhibitor / Wnt activator
Indications: Androgenetic alopecia, chemotherapy-induced alopecia
Route: Topical
CB-03-01
Category: Topical AR antagonist
Indications: Androgenetic alopecia
Route: Topical
GT1718
Category: PGD2 receptor antagonist
Indications: Androgenetic alopecia
Route: Topical
Olumiant / Baricitinib
Category: JAK inhibitor
Indications: Alopecia areata
3. Topical/Research Ingredients
Azelaic Acid
Mechanism: Mild anti-androgen, anti-inflammatory
Caffeine
Mechanism: Stimulates hair follicles, antagonizes DHT inhibition
Retinol / Tretinoin
Mechanism: Promotes epidermal turnover, enhances minoxidil absorption
Peptides
• Copper peptide
• Myristoyl Pentapeptide-17
• Decapeptide-25
Plant Extracts
• Saw Palmetto
• Pumpkin Seed
• Green Tea
• Redensyl
• Anagain (Pisum sativum sprout extract)
• Capixyl (Acetyl Tetrapeptide-3 + Trifolium pratense extract)
4. Alopecia Areata Specialists
- Tofacitinib
- Baricitinib
- Ritlecitinib
- Delgocitinib (topical JAK inhibitor)
5. Simplified Category
| Category | Corresponding Compounds |
|---|---|
| Anti-DHT | Finasteride, Dutasteride, Saw Palmetto |
| Topical Anti-androgens | RU58841, Clascoterone, CB-03-01, Spironolactone |
| Hair Growth Promoters | Minoxidil, WAY-316606, Caffeine, Peptides |
| Anti-inflammatory / PGD2 | Setipiprant, Fevipiprant, GT1718 |
| Alopecia Areata (JAK) | Baricitinib, Ritlecitinib, Tofacitinib |
Hair Loss Compounds — Dosage & Administration
For reference only; not medical advice.
| Compound | Form / Route | Typical Dosage |
|---|---|---|
| Minoxidil | Topical (2%/5%/10% solution/foam) | 2%: 1 mL bid 5%: 1 mL qd/bid Max: 2 mL/day |
| Finasteride | Oral (1 mg tablet) | 1 mg once daily |
| Dutasteride | Oral / Topical (0.005%–0.1% gel/solution) | Oral: 0.5 mg qd Topical: qd |
| RU58841 | Topical (5%–10% solution) | 1–2 mL qd (scalp only) |
| Clascoterone | Topical (5% foam) | 1 capful twice daily |
| WAY‑316606 | Topical (0.1%–0.3% solution) | 1 mL once daily |
| Setipiprant | Oral / Topical (1%–2% solution) | Oral: 1000 mg qd Topical: qd |
| Fevipiprant | Oral | Asthma: 225 mg qd Hair loss: 225–450 mg qd |
| Spironolactone | Oral / Topical (2%–5% solution) | Oral: 25–100 mg qd Topical: qd |
| Tretinoin | Topical (0.01%–0.025%) | 0.5 mL qd (evening) |
| Tofacitinib | Oral / Topical (2% solution/gel) | Oral: 5 mg bid Topical: qd |
| Baricitinib | Oral | 2 mg or 4 mg once daily |
| Ritlecitinib | Oral | 50 mg once daily |
| Azelaic Acid | Topical (5%–10%) | Once or twice daily |
| Caffeine | Topical (0.1%–3%) | Once daily |
| CB‑03‑01 | Topical (1%–3% solution) | Once daily |
| GT1718 | Topical (1%–2% solution) | Once daily |
Disclaimer: This list is for research/educational purposes only and does not constitute medical advice. All medications must be used under the guidance of a professional physician. Do not use any medications without proper medical supervision.